Showing results (1-10 of 167) with videos related to
Sort By:
Pageof 17
Cardiac Failure Review|March 16, 2026
Heart Failure in Hypertrophic CardiomyopathyOlives Nguyen, Daniel Kamna, Ahmad MasriCurrent Opinion in Cardiology|January 17, 2025
New therapies to treat cardiac amyloidosisOlives Nguyen, Daniel Kamna, Ahmad MasriJournal of the American Heart Association|October 28, 2025
Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic CardiomyopathyIngy Mahana, Angelica T Mejia, Miriam R Elman, et al.Journal of the American Heart Association|March 7, 2025
Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic CardiomyopathyBryton J Davis, Hailey Volk, Olives Nguyen, et al.Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|May 16, 2026
Cardiac amyloidosis: Current and pipeline of therapies for the nuclear imagerBryton Davis, Ahmad MasriCurrent Opinion in Cardiology|July 8, 2023
Imaging cardiac hypertrophy in hypertrophic cardiomyopathy and its differential diagnosisLana Rashdan, James Hodovan, Ahmad MasriThe Canadian Journal of Cardiology|January 27, 2024
The Revolution of Cardiac Myosin Inhibitors in Patients With Hypertrophic CardiomyopathyRebecca Haraf, Hany Habib, Ahmad MasriCurrent Heart Failure Reports|October 24, 2023
Differentiating Cardiac Troponin Levels During Cardiac Myosin Inhibition or Cardiac Myosin Activation Treatments: Drug Effect or the Canary in the Coal Mine?Matthew M Y Lee, Ahmad MasriAnnals of Internal Medicine|March 4, 2024
In adults with ATTR cardiac amyloidosis, patisiran reduced decline in functional capacity at 12 moAhmad Masri, Harriette G C Van SpallCurrent Cardiology Reports|April 27, 2023
Baseline and Longitudinal Imaging of Hypertrophic Cardiomyopathy in the Era of Emerging TherapeuticsAhmed Altibi, Ahmad Alani, Yuanzi Zhao, et al.Pageof 17